Paraguay is interested in negotiating with Russia on a cancer vaccine if its effectiveness is confirmed, the Latin American country’s ambassador to Moscow, Victor Hugo Peña Bareiro, said in an interview with RIA Novosti. He said the ambassadors of Latin America and the Caribbean met with representatives of the Russian Ministry of Health, and the parties discussed Russian developments in various fields of medicine.
“Russia has announced significant progress in the development of cancer vaccines. While there is no official confirmation yet, if this progress is verified, it would be remarkable news on a global scale. Paraguay aims to be among the first countries to engage with Russia on this matter”, the diplomat stated.
Earlier, it was announced that Russia has started clinical trials of the new EnteroMix oncolytic vaccine with 48 volunteers participating. The drug was developed by the Russian Ministry of Health’s National Medical Research Radiological Centre in collaboration with the Engelhardt Institute of Molecular Biology (EIMB) of the RAS.
Another Russian therapeutic cancer vaccine has also completed its clinical trials. The mRNA vaccine was developed by the N. N. Blokhin National Research Medical Center, Gamaleya National Research Center for Epidemiology and Microbiology, and the P. Hertsen Moscow Oncology Research Institute.
This vaccine will be personalized, meaning it will be tailored to each patient individually. Aleksandr Ginzburg, the director of the Gamaleya Center, earlier said that regulators plan to approve a strategy for its development and application in the coming months. He states that the first patients could begin receiving treatment with the domestic drug as early as September or October 2025.
